Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Other Non-Current Liabilities (2016)

RedHill Biopharma has reported Other Non-Current Liabilities over the past 6 years, most recently at $1.1 million for Q4 2016.

  • Quarterly Other Non-Current Liabilities changed 0.0% to $1.1 million in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2016, changed 0.0% year-over-year, with the annual reading at $1.1 million for FY2016, 0.0% changed from the prior year.
  • Other Non-Current Liabilities was $1.1 million for Q4 2016 at RedHill Biopharma, roughly flat from $1.1 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $3.3 million in Q4 2012 and troughed at $1.1 million in Q1 2015.
  • The 5-year median for Other Non-Current Liabilities is $1.5 million (2014), against an average of $1.7 million.
  • Year-over-year, Other Non-Current Liabilities increased 21.85% in 2012 and then plummeted 52.72% in 2014.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $3.3 million in 2012, then tumbled by 42.96% to $1.9 million in 2013, then decreased by 18.16% to $1.5 million in 2014, then tumbled by 30.82% to $1.1 million in 2015, then changed by 0.0% to $1.1 million in 2016.
  • Per Business Quant, the three most recent readings for RDHL's Other Non-Current Liabilities are $1.1 million (Q4 2016), $1.1 million (Q3 2016), and $1.1 million (Q2 2016).